What’s New In 2023: Exciting Plans For Upperton Pharma Solutions
January 31st 2023 : Newsletter The New Year is always a time for looking ahead and 2023 will no doubt turn out to be a pivotal year in the Upperton Pharma Solutions growth story. In this Newsletter we will be previewing some of the exciting new plans that we have in store for ourselves and […]
Upperton’s new Nottingham facility
18th January 2023 Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has begun construction work for its new Development and GMP Manufacturing headquarters in Nottingham, UK. Working in close collaboration with its principal Design and Build contractor, T-SQUARED the team officially broke ground on the […]
2022: A year of unparalleled growth for Upperton
December 21st 2022 : Newsletter Traditionally at this time of year we like to offer Season’s Greetings to all our customers and friends and whilst doing so, look back over the years at some of the highlights in what has been an exceptionally busy (and successful) year for Upperton Pharma Solutions! Here are just a […]
Build of New Development and Manufacturing Facility
29th November 2022 – Press Release & Newsletter Upperton Pharma Solutions Appoints T-SQUARED for Design and Build of New Development and Manufacturing Facility Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has appointed T-SQUARED, UK based company, as the principal Design and Build contractor for […]
Upperton Launches ASAPprime® Shelf-Life Stability Testing
November 16th 2022 : Newsletter Upperton has made a significant investment in ASAPprime® software and hardware to enable the company to offer its clients state of the art stability testing. This exciting new platform can be used to generate robust, accelerated chemical stability data and is now being applied at all stages of the product […]
In Vitro Testing of Dry Powder Nasal Delivery Devices
Successful nasal drug delivery of dry powder formulations requires a delivered dose that can penetrate beyond the nasal entrance region and deposit in the peripheral nasal cavity, whilst avoiding deeper penetration to the airways of the lungs. This delivery, or deposition pattern, is determined by the aerodynamic particle size of the powder exiting the device, […]
Successful MHRA Inspection & New Capsule Filling Technology
August 16th 2022 : Newsletter Upperton is delighted to announce that during the last week of July 2022 the UK MHRA conducted a routine, three day inspection of the GMP facility and Quality Control testing laboratories following which, no Critical or Major observations were raised. Speaking after the inspection, CEO Nikki Whitfield was quick to […]
Characterising the Physical Properties of Spray Dried Powders
The Benefits of Powder Characterisation When developing products containing spray dried powders it is vital that the physical properties of the powders produced are determined. The physical properties of spray dried powders provides important information that can assist during the pre-formulation screening and early process development phases since these properties will have a direct impact […]
Upperton Pharma Solutions Announces £15m Investment in Trent Gateway Facility
23rd May 2022 : Press Release Upperton Pharma Solutions (Upperton), a UK-based specialist contract development and manufacturing organisation (CDMO), has announced a circa. £15m investment into the design and build of a 50,000 sq ft facility in Nottingham. The new facilities will allow a significant increase in research and development laboratory space and a 10-fold […]
Inflexion announces investment into Upperton
21st April 2022 – Press Release Inflexion is pleased to announce it has made a substantial investment into Upperton Pharma Solutions (“Upperton”), a UK-based specialist contract development and manufacturing organisation (“CDMO”) which has expertise in particle engineering for the pharmaceutical industry. Inflexion has invested alongside the founder and the management team who will continue to […]